Venture Capital

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

A DoW contract for in-orbit refueling thrusts Quantum Space into the spotlight, promising to redefine space warfare and ignite the orbital logistics economy.

With a fresh $260M, Dream is building AI for nations to own. But as governments rush for digital autonomy, are we creating a new digital iron curtain?

UAE-based Robo.ai is acquiring a venture builder with a $60M all-stock deal tied to a staggering $2.4B revenue target. Is this visionary ecosystem-building or a high-risk bet?

With 2.25M developers and advanced hybrid cloud adoption, India isn't just joining the cloud native world; it's rewriting the rules for global innovation.

A startup's new MR glasses challenge Microsoft HoloLens, but the real story is its bold play to fuel the physical AI revolution with specialized data hardware.

Netlist's new patent lawsuits over HBM and DDR5 memory could disrupt the AI supply chain, putting the tech giants' critical components in legal peril.

Office Properties Income Trust emerges from bankruptcy with $714M less debt and new owners. Is its strategic overhaul a model for a sector in crisis?

As RESTEM presents at BIO 2026, the company showcases its novel cell therapies aiming to reprogram the immune system, not just manage symptoms.

Sharon AI's massive financing reveals a deeper story: a global race to build the physical backbone for AI, fueled by visionary bets and cautious capital.

Activist investor Saba Capital has ousted the board of Impax Environmental Markets, a stunning victory fueled by chronic underperformance. What does this mean?

As enterprises deploy autonomous AI agents, a new class of threats emerges. A startup founded by Cisco veterans says it can stop attacks before they happen.

TAE Technologies hires an Exxon Mobil veteran to build its first fusion plant, but a bizarre, unconfirmed merger claim with Trump's media group raises eyebrows.

As tech IPOs stall, a new breed of private credit fund offers a lifeline to employees with 'paper wealth,' unlocking billions in value from top unicorns.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

A return to profit and a 4.6p special dividend signal success for Octopus AIM VCT. But a deeper look reveals a masterclass in strategic exits and a VCT sector at a crossroads.

A Burkinabe court nullified a key stream deal, but Franco-Nevada says Ontario law governs. The dispute is a flashpoint for geopolitical risk.

Mastercard's $10,000 grants are just the headline. The real story is the ecosystem it's building to fix a broken funding model for women entrepreneurs.

The G7 unveils a plan to replace traditional aid with 'mutually beneficial partnerships.' But can this ambitious overhaul fix a broken system and tame a debt storm?